Shanghai, China
Jixing Pharmaceuticals, founded in 2019, is a biopharmaceutical company based in Shanghai, China. The company's slogan, "Our mission is to develop novel therapeutics, bridging the innovation gap for patients in China," reflects its dedication to bringing innovative science and medicines to underserved patients in China with serious and life-threatening diseases.
Backed by RTW Investments, LP, Jixing Pharmaceuticals specializes in partnering with global biotechnology companies to develop and commercialize novel, innovative therapeutics, particularly focusing on addressing unmet medical needs in cardiovascular and ophthalmic diseases. With a strong and continually advancing asset pipeline, the company has a seasoned management team and a patient-centric focus, aiming to have a meaningful and lasting impact on patients in China.
Jixing Pharmaceuticals boasts a robust cardiovascular portfolio that includes 3 assets in late-stage clinical development (Aficamten, Etripamil, Omecamtiv Mecarbil) and 1 in pre-clinical stage (JX09). In ophthalmology, the company's portfolio comprises 4 assets in late-stage clinical development (varenicline solution nasal spray/US brand name TYRVAYA, OC-02 nasal spray, JX06/LNZ100, JX07/LNZ101) and 1 asset in pre-clinical stage (JX08).
The company recently secured a notable $162.00M Series D investment on 06 January 2024, with key investors including Leaps by Bayer and RTW Investments. Jixing Pharmaceuticals' focus on addressing critical healthcare needs in China, coupled with its strong investment backing and promising pipeline, positions it as a compelling player in the biotechnology and healthcare industries.
